Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)

Hinterhaus Productions Iovance's Strong Q2 Reinforces Case for Amtagvi's Success Following its accelerated approval in melanoma earlier this year, Iovance's (NASDAQ:IOVA) Amtagvi (lifileucel) became the first T cell therapy to be approved for a solid tumor. The achievement came after decades of research into tumor-infiltrating lymphocytes, or TIL therapy. In my previous article on Iovance, I acknowledged that, while Amtagvi was a significant step forward, it faces challenges due to its high cost, intensive ...